Is Concurrent Chemoradiation the Standard of Care for Locally Advanced Non-small Cell Lung Cancer? A Review of Guidelines and Evidence

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

“…22,35,64 However, given the advances in treatment, in the areas of both CTX and RT, it was felt worthwhile to examine the question again and to limit the dates of included trials to represent current, rather than historical, clinical practice.…”

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

“…The reason is that most patients are not surgical candidates because of the advanced disease stage at diagnosis, poor clinical condition, and comorbidities. 25 O'Rourke et al 26 reported that CCRT is the standard of care in local advanced NSCLC with a median survival rate of approximately 21 months. McCloskey et al 27 found that CCRT decreases loco-regional progression (hazard ratio [HR] ¼ 0.77; P ¼ 0.01), which translates into a significant survival benefit (HR, 0.84; 95% CI, 0.74-0.95; P ¼ 0.004).…”

Rapid Learning in Practice: A Lung Cancer Survival Decision Support System in Routine Patient Care Data

“…In the developed world, 85% of cases are non-small cell lung cancer (NSCLC) patients and 44% present with non-metastatic disease, for whom primary radical surgery or radiotherapy, in combination with chemotherapy, is indicated [2]. The outcome of inoperable NSCLC undergoing radical (chemo)radiotherapy is bleak with two-year overall survival (2 year-OS) rates reported as approximately 50% in early stage (stage I-II) patients [3] and 25% in locally advanced cancers (stage IIIA-IIIB) [4]. To improve survival, more individualized radiotherapy schedules have been proposed with encouraging results [5].…”